Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleFeatured Article of the Month

Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas

Manuel Röhrich, Patrick Naumann, Frederik L. Giesel, Peter L. Choyke, Fabian Staudinger, Annika Wefers, Dawn P. Liew, Clemens Kratochwil, Hendrik Rathke, Jakob Liermann, Klaus Herfarth, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Matthias Lang and Stefan A. Koerber
Journal of Nuclear Medicine June 2021, 62 (6) 779-786; DOI: https://doi.org/10.2967/jnumed.120.253062
Manuel Röhrich
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Naumann
2Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor diseases (NCT), Heidelberg, Germany
4Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik L. Giesel
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
5German Cancer Consortium (DKTK), partner site Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter L. Choyke
6Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabian Staudinger
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annika Wefers
7Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
8Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn P. Liew
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrik Rathke
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob Liermann
2Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor diseases (NCT), Heidelberg, Germany
4Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Herfarth
2Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor diseases (NCT), Heidelberg, Germany
4Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Jäger
9Department of Medical Oncology and Internal Medicine Virgin Islands, National Center for Tumor Diseases, University Hospital Heidelberg, Germany
10Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Debus
2Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor diseases (NCT), Heidelberg, Germany
4Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany
5German Cancer Consortium (DKTK), partner site Heidelberg, Germany
11Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
12Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
5German Cancer Consortium (DKTK), partner site Heidelberg, Germany
13Clinical Cooperation Unit, Department of Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
14Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Lang
7Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
15Department of Surgery, Heidelberg University Hospital, Heidelberg, GermanyMember of the German Center for Lung Research DZL, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan A. Koerber
2Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor diseases (NCT), Heidelberg, Germany
4Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (6)
Journal of Nuclear Medicine
Vol. 62, Issue 6
June 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
Manuel Röhrich, Patrick Naumann, Frederik L. Giesel, Peter L. Choyke, Fabian Staudinger, Annika Wefers, Dawn P. Liew, Clemens Kratochwil, Hendrik Rathke, Jakob Liermann, Klaus Herfarth, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Matthias Lang, Stefan A. Koerber
Journal of Nuclear Medicine Jun 2021, 62 (6) 779-786; DOI: 10.2967/jnumed.120.253062

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
Manuel Röhrich, Patrick Naumann, Frederik L. Giesel, Peter L. Choyke, Fabian Staudinger, Annika Wefers, Dawn P. Liew, Clemens Kratochwil, Hendrik Rathke, Jakob Liermann, Klaus Herfarth, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Matthias Lang, Stefan A. Koerber
Journal of Nuclear Medicine Jun 2021, 62 (6) 779-786; DOI: 10.2967/jnumed.120.253062
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
  • Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
  • Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions
  • 18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma
  • Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
  • Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics
  • Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
  • 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
  • Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
  • Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
  • Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
  • Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
  • 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
  • Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
  • Static and Dynamic 68Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas
  • Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions
  • Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis
  • Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
  • Google Scholar

More in this TOC Section

  • MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
  • IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
  • Pilot Study of Nectin-4–Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human
Show more FEATURED ARTICLE OF THE MONTH

Similar Articles

Keywords

  • fibroblast activation protein
  • FAP
  • pancreatic ductal adenocarcinoma
  • PDAC
  • PET
  • TNM
  • staging
SNMMI

© 2025 SNMMI

Powered by HighWire